van Leeuwen R, Katlama C, Murphy RL (May 2003). "A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients". AIDS. 17 (7): 987—99. doi:10.1097/00002030-200305020-00007. PMID12700448.
van Leth F, Andrews S, Grinsztejn B (March 2005). "The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART". AIDS. 19 (5): 463—71. doi:10.1097/01.aids.0000162334.12815.5b. PMID15764851.
Guay LA, Musoke P, Fleming T (Sep 1999). "Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial". Lancet. 354 (9181): 795—802. doi:10.1016/S0140-6736(99)80008-7. PMID10485720.
Jourdain G, Ngo-Giang-Huong N, Le Coeur S (Jul 2004). "Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy". N Engl J Med. 351 (3): 229—40. doi:10.1056/NEJMoa041305. PMID15247339.
Conway B, Wainberg MA, Hall D (Jul 2001). "Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine". AIDS. 15 (10): 1269—74. doi:10.1097/00002030-200107060-00008. PMID11426071.
drugs.com
"Nevirapine" (неопр.). The American Society of Health-System Pharmacists. Дата обращения: 5 мая 2021. Архивировано 20 декабря 2016 года.
van Leeuwen R, Katlama C, Murphy RL (May 2003). "A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients". AIDS. 17 (7): 987—99. doi:10.1097/00002030-200305020-00007. PMID12700448.
Podzamczer D, Ferrer E, Consiglio E (2002). "A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)". Antiviral Therapy. 7 (2): 81—90. PMID12212928.
van Leth F, Andrews S, Grinsztejn B (March 2005). "The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART". AIDS. 19 (5): 463—71. doi:10.1097/01.aids.0000162334.12815.5b. PMID15764851.
Guay LA, Musoke P, Fleming T (Sep 1999). "Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial". Lancet. 354 (9181): 795—802. doi:10.1016/S0140-6736(99)80008-7. PMID10485720.
Jourdain G, Ngo-Giang-Huong N, Le Coeur S (Jul 2004). "Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy". N Engl J Med. 351 (3): 229—40. doi:10.1056/NEJMoa041305. PMID15247339.
Conway B, Wainberg MA, Hall D (Jul 2001). "Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine". AIDS. 15 (10): 1269—74. doi:10.1097/00002030-200107060-00008. PMID11426071.